What is VIR's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.98B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for VIR?

P/E (TTM) is n/a and 52-week range is $4.82 to $11.94 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s VIR figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for VIR?

The company profile lists revenue (TTM) near $303M, net income (TTM) near $-12.58B, EPS (TTM) near $-1.01 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Vir Biotechnology Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Francisco, California, US, 168.7M shares outstanding, ISIN US92764N1028 when available from company profile and filing metadata.

Vir Biotechnology Inc (VIR) Stock Analysis & Quote

Vir Biotechnology Inc

$VIR

Health Care · Biotechnology

IR Run Scenarios

$11.70

+5.22%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 367 full-time employees. The company went IPO on 2019-10-11. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. The company also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. The company also has rights to the PRO-XTEN masking platform for oncology and infectious disease.

Employees

367

Website

www.vir.bio/

IPO

2019-10-11

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)